Business, energy, technology, markets and global industry news from Business News Today

European Respiratory Society

PharmaDeviceNews European Respiratory Society
Representative image of gene-editing research targeting inherited lung and liver disease as Serapha Bio’s SERP-01 restores protective alpha-1 antitrypsin protein levels in early clinical testing, showing promise for a one-time treatment.
Pharma & Biotech

SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease

Serapha Bio's SERP-01 gene editing restores protective protein levels in four AATD patients. Explore the early results and Phase 2/3 plans.

Read More
Representative image: A nebulized respiratory therapy setup illustrates the clinical focus behind AeroRx Therapeutics’ AERO-007 Phase 2a COPD data, as researchers evaluate whether once-daily LABA+LAMA nebulized treatment can address persistent delivery challenges in chronic obstructive pulmonary disease care.
Pharma & Biotech

Mabwell reports 81% fewer COPD exacerbations at highest 9MW1911 dose. Why the number needs caution

Mabwell’s 80-patient Phase 1b/2a COPD trial showed an 81% numerical reduction in moderate-to-severe exacerbations at the highest 9MW1911 dose, supporting Phase 2b and planned Phase 3 development.

Read More
A representative image illustrating BEAM-302 base-editing research as Beam Therapeutics begins pivotal testing of its one-time investigational treatment for alpha-1 antitrypsin deficiency affecting the lungs and liver.
Pharma & Biotech

First patient dosed in BEAM-302 pivotal cohort for alpha-1 antitrypsin deficiency

BEAM-302 enters pivotal AATD testing after early base-editing data. Read how the study could support an accelerated approval pathway.

Read More